Integra LifeSciences Holdings Corporation (NASDAQ: IART) has reported its financial results for the fourth quarter and full year ended December 31, 2025.
In the fourth quarter of 2025, reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024. Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024.
For the full year 2025, reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and a decrease of 0.7% on an organic basis compared to full-year 2024. GAAP earnings per diluted share were $(6.74), compared to $(0.09) in 2024. Adjusted earnings per diluted share were $2.23, compared to $2.56 in 2024.
The company reported a GAAP net loss of $(1.7) million, or $(0.02) per diluted share, in the fourth quarter of 2025, compared to GAAP net income of $19.4 million, or $0.25 per diluted share, in the prior year. Adjusted EBITDA for the fourth quarter of 2025 was $104.2 million, compared to $104.9 million in the fourth quarter of 2024. Adjusted net income for the fourth quarter of 2025 was $63.7 million, or $0.83 per diluted share, compared to adjusted net income of $73.3 million, or $0.97 per diluted share, in the fourth quarter of 2024.
The company's full-year 2025 adjusted EBITDA was $317.5 million, a decrease of $4.7 million versus the prior year. Full-year adjusted EBITDA margins were 19.4%, a decrease of 60 basis points from the prior year period. Adjusted net income for the full-year 2025 was $171.4 million, or $2.23 per diluted share, compared to $196.9 million, or $2.56 per diluted share in the prior year.
The company generated cash flow from operations of $50.4 million for the full-year 2025. Full-year capital expenditures were $81.4 million. The company's net debt at the end of the year was $1.6 billion, and the consolidated total leverage ratio was 4.5x.
Looking ahead to 2026, the company expects revenues to be in the range of $1,662 million to $1,702 million, representing reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3%. Adjusted earnings per diluted share are expected to be between $2.30 and $2.40.
The company is hosting a conference call to discuss the financial results and forward-looking financial guidance.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global medical technology leader dedicated to restoring lives. As a result of these announcements, the company's shares have moved -1.9% on the market, and are now trading at a price of $12.41. For more information, read the company's full 8-K submission here.
